Loading clinical trials...
Loading clinical trials...
A Multicenter, Open-label Study to Collect the Safety Information of Sacubitril/Valsartan in Japanese Pediatric Patients With Heart Failure Due to Systemic Left Ventricle Systolic Dysfunction Who Have Completed CLCZ696B2319E1 Study
The purpose of this open-label study was to collect additional safety information of sacubitril/valsartan and to provide post-trial access to sacubitril/valsartan for the eligible Japanese patients who completed CLCZ696B2319E1(NCT03785405) study until marketed product of pediatric formulation, film-coated granules in capsule, is available in Japan.
This trial (CLCZ696B2319E2) was a multicenter, open-label extension study for Japanese patients who have successfully completed the CLCZ696B2319E1 study. Only Japanese patients who successfully completed CLCZ696B2319E1 study and fulfilled protocol requirements were eligible to participate in this study. The first visit (Visit Day1) was the same day as the End of Study visit of CLCZ696B2319E1 study.
Age
3 - 18 years
Sex
ALL
Healthy Volunteers
No
Novartis Investigative Site
Ōbu, Aichi-ken, Japan
Novartis Investigative Site
Ōmura, Nagasaki, Japan
Novartis Investigative Site
Bunkyo Ku, Tokyo, Japan
Novartis Investigative Site
Setagaya-ku, Tokyo, Japan
Novartis Investigative Site
Saitama, Japan
Novartis Investigative Site
Toyama, Japan
Start Date
December 4, 2023
Primary Completion Date
August 14, 2024
Completion Date
August 14, 2024
Last Updated
October 14, 2025
8
ACTUAL participants
sacubitril/valsartan
DRUG
Lead Sponsor
Novartis Pharmaceuticals
NCT07191730
NCT07484009
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions